Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc., a leading biotechnology company based in the United States, focuses on developing innovative therapies for neurological disorders. Founded in 1995, Acorda has made significant strides in the industry, particularly with its core products aimed at improving mobility and quality of life for patients with conditions such as multiple sclerosis and spinal cord injury. Headquartered in Ardsley, New York, Acorda operates primarily in the US, with a commitment to advancing scientific research and clinical development. The company’s flagship products, including Ampyra, are distinguished by their unique mechanisms of action that enhance walking ability in patients. Acorda's dedication to innovation and patient-centric solutions has solidified its position as a notable player in the biotechnology sector, contributing to advancements in neurological care.
DitchCarbon Score
How does Acorda Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Acorda Therapeutics, Inc.'s score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Acorda Therapeutics, Inc.'s reported carbon emissions
Acorda Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their Scope 1, 2, or 3 emissions. The absence of emissions data suggests that Acorda may still be in the early stages of formalising its climate commitments or reporting practices. In the context of the biopharmaceutical industry, companies are increasingly recognising the importance of sustainability and are encouraged to establish clear climate goals and reduction initiatives. Acorda's future commitments in this area will be crucial for aligning with industry standards and addressing climate change effectively.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Acorda Therapeutics, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
